Tempest Therapeutics (TPST)

• Market cap: $33.6M
• 1 day: 8.22%
• 5 days: -5.68%
• 1 month: -15.85%
• 3 months: -40.76%
• 6 months: -63.15%
• Year to date: -82.54%
• 1 year: -82.85%
• 5 years: -94.24%
• 10 years: -94.24%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Employees: 17

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

17% more funds holding

Funds holding: 24 [Q2] → 28 (+4) [Q3]

1.28% more ownership

Funds ownership: 9.95% [Q2] → 11.23% (+1.28%) [Q3]

18% less capital invested

Capital invested by funds: $4.84M [Q2] → $3.94M (-$895K) [Q3]

28% less call options, than puts

Call options by funds: $117K | Put options by funds: $163K

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 549% upside
• Avg. target: $26 3,276% upside
• High target: $47 6,003% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target	549% upside $5	Overweight Maintained	13 Nov 2024
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 79 / 384 met price target	6,003% upside $47	Buy Reiterated	13 Nov 2024